Projects and Grants
GU Cancer Database: Creating and maintaining a high quality database and GU tumor bank in which clinical data and biological specimens are collected and stored to support basic and translational research
Predicting Response to Platinum Chemotherapy in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Using a Genomic Signature for ‘BRCA-ness’: 1) Identify a clinical and pathologic phenotype of men with prostate cancers which express a ‘BRCA-ness’ signature base on known germline BRCA1 and 2 breast cancers 2) Conduct a prospective trial of oral satraplatin as second-line chemotherapy for metastatic CRPC and correlate response and survival to the ‘BRCAness’ signature.
Multi-center Phase IB/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide As First-Line Therapy for Patients with Metastatic Urothelial Carcinoma: Determine the recommended dose of the combination of gemcitabine, cisplatin, plus lenalidomide in patients with metastatic urothelial carcinoma and evaluate the activity of this regimen as determined by the objective response rate.
Multi-center Phase II Trial of Single-Agent Amrubicin as Second-Line Therapy in Patients with Advanced/Metastatic Refractory Urothelial Carcinoma: Determine the objective response rate to treatment with amrubicin.
1425 Madison Avenue,1st Floor
New York, NY 10029